BMAC for Back Pain

Could BMAC Help Your Back?

Discogenic low back pain — pain arising from the intervertebral disc itself rather than nerve compression or facet joints — is one of the most challenging pain conditions to treat. Conservative care helps many patients, but for those with confirmed disc degeneration who have not found lasting relief, regenerative options including intradiscal BMAC injection represent an emerging avenue worth understanding.

This page presents what the current evidence supports and where it falls short — because honest patient education is the foundation of good clinical decision-making.

What Is Discogenic Low Back Pain?

Discogenic pain originates from degenerative changes within the intervertebral disc — including disc desiccation, annular tears, loss of disc height, and loss of the disc’s normal hydration and shock-absorbing capacity. Patients typically describe:

  • Deep, achy low back pain worsened by sitting, bending, lifting, or transitioning from sitting to standing
  • Pain that is predominantly in the low back rather than radiating significantly into the leg
  • Symptoms that have persisted despite physical therapy, oral medications, and conventional injections

Confirmation of discogenic pain as the primary pain generator is essential before considering intradiscal injection of any kind — including BMAC.

What Is BMAC and How Does It Work in the Disc?

Bone Marrow Aspirate Concentrate (BMAC) is derived from a small sample of your own bone marrow, typically drawn from the pelvis under local anesthesia. The sample is processed the same day to concentrate mesenchymal stem cells, growth factors, platelets, and anti-inflammatory signaling proteins.

When injected directly into a degenerative disc under fluoroscopic (x-ray) guidance, these biological signals may help:

  • Modulate the inflammatory environment within the disc
  • Support disc cell health and slow further degeneration
  • Improve the disc’s biological capacity for self-repair
  • Reduce discogenic pain and improve functional tolerance

BMAC does not rebuild disc height, restore normal disc architecture, or reverse advanced structural damage. The goal is biological modulation — creating conditions that support the disc’s own healing mechanisms.

What the Evidence Shows — The Case For BMAC

Systematic reviews and cohort studies:

  • A systematic review of 16 studies involving 607 participants found that intradiscal BMAC generally provided improved pain intensity and physical function compared to baseline, with follow-up ranging from one to six years. More than 70% of participants avoided spine surgery through the follow-up period, and opioid use decreased significantly
  • A prospective cohort study of 32 patients with primary discogenic low back pain found meaningful improvements in pain scores, disability ratings, and quality of life at one year following intradiscal BMAC injection
  • A 2025 review of non-surgical treatments for lumbar disc conditions concluded that BMAC promotes tissue regeneration and alleviates symptoms in clinical studies, with some patients showing favorable changes on follow-up MRI including improved disc height and Pfirrmann grading

Randomized controlled trial:

  • A multicenter, prospective, randomized controlled trial found PRP and BMAC equally effective at 12 months for discogenic low back pain. All placebo patients who crossed over to a biologic group demonstrated significant improvements in pain, function, and satisfaction scores — suggesting genuine biological activity beyond placebo for orthobiologic injections as a class

Long-term data:

  • A case series with at least six years of follow-up in patients treated with intradiscal biologic injections reported sustained pain and functional improvements, suggesting that benefits may persist well beyond the one to two year follow-up periods of most studies

What the Evidence Shows — The Case for Caution

The negative evidence for intradiscal BMAC in low back pain is significant and should be understood clearly before making any treatment decision:

  • The strongest negative study: A 2025 double-blind, randomized, sham-controlled trial — the highest quality study design available — found intradiscal BMAC equivalent to a sham procedure for chronic discogenic low back pain. Both groups showed similar improvement rates at 3, 6, and 12 months. This raises the serious possibility that a meaningful portion of the benefit seen in uncontrolled studies reflects placebo response rather than true biological treatment effect
  • Quality of evidence: A systematic review using the GRADE evidence framework rated the overall quality of evidence supporting intradiscal biologic agents including BMAC as very low — citing small sample sizes, insufficient blinding, and heterogeneous patient populations across studies
  • Publication bias: A 2024 analysis found that most clinical trials in disc regeneration failed to reach publication, with available reports showing only minor improvements — raising real concerns that negative results are being systematically underreported
  • No structural restoration: Even in studies reporting positive outcomes, follow-up MRI findings showed inconsistent improvements in disc structure — most patients did not demonstrate meaningful changes in Pfirrmann grade or disc height despite reporting pain improvement
  • Serious adverse events: While rare, discitis (spinal disc infection) has been reported following intradiscal injection. Rigorous patient selection, sterile technique, and appropriate antibiotic prophylaxis are essential
  • No consensus guidelines: Unlike knee osteoarthritis where ACR conditionally recommends orthobiologics, no major spine society has issued formal recommendations supporting routine intradiscal BMAC for low back pain

What This Means for Patient Selection

The honest clinical picture is this: intradiscal BMAC for discogenic low back pain shows promise in observational studies but has not yet been validated by high-quality controlled trials. The 2025 sham-controlled trial is a significant finding that cannot be dismissed. At the same time, the multicenter RCT showing genuine benefit over placebo when patients cross over to biologics suggests there may be a real treatment effect in the right patients.

Patient selection is therefore critical. Intradiscal BMAC may be worth considering if you have:

  • Chronic discogenic low back pain confirmed by clinical history, physical examination, and imaging findings consistent with disc pathology
  • Adequate disc height retained — severe disc collapse is generally a contraindication
  • Low back pain that has not responded adequately to physical therapy, oral medications, and conventional injections
  • No significant neurological compromise or nerve compression as the primary pain generator
  • A preference to delay or avoid spinal fusion or disc replacement surgery — with a clear understanding that the evidence base is still evolving and outcomes are not guaranteed

Intradiscal BMAC is generally not recommended for:

  • Axial low back pain where the disc has been ruled out as the primary pain generator
  • Severe disc collapse or advanced structural instability
  • Significant radiculopathy or neurological deficits where nerve compression is the primary issue
  • Cases where spinal surgery is immediately indicated
  • Patients with active infection, malignancy, bleeding disorders, or other procedural contraindications

Before Your Procedure

Avoid NSAIDs (such as ibuprofen, Mobic, naproxen, or Celebrex) for at least one week before and one week after your BMAC procedure. NSAIDs interfere with the inflammatory signaling that drives the treatment’s effectiveness.

What to Expect

The procedure involves two components performed in the same session at an accredited ambulatory surgery center (ASC):

Bone marrow aspiration: Performed under local anesthesia, a small sample of bone marrow is drawn from the posterior iliac crest of the pelvis. Most patients describe this as a brief pressure sensation.

Intradiscal injection: The processed BMAC is injected directly into the affected disc under fluoroscopic guidance to confirm accurate placement. Antibiotic prophylaxis is administered to minimize infection risk.

The full procedure typically takes one to two hours. Most patients return to light activity within a few days. Mild soreness at both the aspiration and injection sites is common for several days following the procedure. Meaningful improvements in pain and function, when they occur, typically develop gradually over four to twelve weeks.

From a Research & Clinical Perspective

The evidence for intradiscal BMAC in discogenic low back pain is genuinely mixed. Observational studies and some controlled trials report meaningful improvements in pain, function, and quality of life, with the majority of patients avoiding surgery through follow-up periods of up to six years. However, the most rigorous study to date — a 2025 double-blind sham-controlled trial — found no difference between BMAC and placebo, and the overall quality of evidence across studies is rated very low by GRADE standards. Publication bias may be inflating the apparent positive signal in the literature.

Dr. Murakami will review the current evidence alongside her clinical experience to discuss what is most appropriate for your specific condition and whether intradiscal BMAC is a reasonable option for you.

Sources & Further Reading

The following peer-reviewed studies informed the content on this page. Links open in a new tab.

Supporting Evidence

Negative and Limiting Evidence

This page was last reviewed March 2026.

BMAC Consultation in Walnut Creek